FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023396018> ?p ?o ?g. }

• W2023396018 endingPage "559" @default.
• W2023396018 startingPage "558" @default.
• W2023396018 abstract "Previous studies suggest that growth hormone (GH) deficiency is associated with an increased risk of cardiovascular morbidity and mortality.1 Several studies have demonstrated hypercholesterolemia and hypertriglyceridemia in both children and adults with GH deficiency.2 However, the effects of GH replacement therapy on serum lipids in GH-deficient children have been inconsistent, and no previous prospective studies on the effects of GH on lipoprotein metabolism in GH-deficient adults have been reported. In this study, the authors describe the effects of 6 months of physiologic GH replacement therapy on serum lipids and lipoproteins in 24 adults with GH deficiency. The effects of GH replacement on body composition and metabolism were previously reported in these individuals.3 In that report, GH improved indices of lean body mass and diminished fat mass during a 6-month period; the current study extends the previous finding of decreased serum cholesterol levels during GH treatment.3 Patients (aged 18 to 52 years) with documented GH deficiency secondary to pituitary surgery or irradiation comprised the study group. The patients were receiving conventional and stable doses of pituitary hormone replacement therapy as required (glucocorticoids, thyroxine, and sex steroids). Those with underlying diseases or those taking drugs known to affect lipid metabolism were excluded. Sex- and age-matched healthy control subjects were also studied. The patients received recombinant GH (0.07 U/kg·day−1 or = 0.025 mg/kg·day−1, subcutaneously) or subcutaneous saline placebo daily for 6 months in a double-blind manner. The two groups of patients were matched for age, sex, height, and weight at entry. Venous blood was taken at 9 AM after an overnight fast before treatment and after 1, 3, and 6 months of treatment, and the lipid and lipoprotein concentrations were analyzed. Results are expressed as mean ± SEM. Compared with non-GH-deficient healthy controls, GH-deficient subjects exhibited significant abnormalities in several circulating lipoproteins before treatment. GH-deficient patients had higher serum levels of total cholesterol (control 4.89 ± 0.17 mmol/L vs GH deficient 5.85 ± 0.22; p =.02), triglycerides (1.24 ± 0.09 mmol/L vs 2.18 ± 1.24; p =.017), low-density lipoprotein (LDL) cholesterol (3.06 ± 0.16 mmol/L vs 4.10 ± 0.20; p <.001), and apolipoprotein B (apo B) (0.84 ± 0.04 g/L vs 1.01 ± 0.05; p =.011), and significantly lower levels of serum high-density lipoprotein (HDL) cholesterol (control 1.26 ± 0.06 mmol/L vs GH deficient 0.83 ± 0.06; p <.001). The percentage of patients with elevated serum lipids or lipoproteins more than two standard deviations from the control mean was 39% for total cholesterol, 26% for triglycerides, 39% for LDL cholesterol, 25% for apo B, and 70% for the LDL to HDL cholesterol ratio. In the randomized portion of the study, GH treatment significantly decreased serum cholesterol levels (by 12%) compared with placebo treatment (by repeated measures analysis of variance), decreased LDL cholesterol by 32%, and decreased apo B levels by 37%. HDL cholesterol levels tended to rise with GH (not significant), and the LDL to HDL ratio fell significantly (from 5.57 ± 0.47 at entry to 3.29 ± 0.33 in GH-treated patients vs no change in placebo controls). No significant change in free fatty acids or triglycerides occurred with GH over time. The alterations in lipid and lipoprotein levels were not significantly correlated with insulin, insulin-like growth factor-I, glucagon, thyroid hormone levels, or indices of adiposity (fat mass, multiple skin-fold measurements)." @default.
• W2023396018 created "2016-06-24" @default.
• W2023396018 creator A5011822494 @default.
• W2023396018 date "1994-11-01" @default.
• W2023396018 modified "2023-09-25" @default.
• W2023396018 title "Growth Hormone Treatment Improves Serum Lipids and Lipoproteins in Adults With Growth Hormone Deficiency R. C. CUNEO, F. SALOMON, G. F. WATTS, ET AL Metabolism 42:1519-1523, 1993" @default.
• W2023396018 cites W2017800123 @default.
• W2023396018 cites W2032772016 @default.
• W2023396018 cites W2120108803 @default.
• W2023396018 cites W2315987042 @default.
• W2023396018 cites W2331609610 @default.
• W2023396018 doi "https://doi.org/10.1177/0148607194018006558" @default.
• W2023396018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7602734" @default.
• W2023396018 hasPublicationYear "1994" @default.
• W2023396018 type Work @default.
• W2023396018 sameAs 2023396018 @default.
• W2023396018 citedByCount "0" @default.
• W2023396018 crossrefType "journal-article" @default.
• W2023396018 hasAuthorship W2023396018A5011822494 @default.
• W2023396018 hasConcept C120863210 @default.
• W2023396018 hasConcept C126322002 @default.
• W2023396018 hasConcept C134018914 @default.
• W2023396018 hasConcept C142724271 @default.
• W2023396018 hasConcept C147583825 @default.
• W2023396018 hasConcept C204787440 @default.
• W2023396018 hasConcept C27081682 @default.
• W2023396018 hasConcept C2776919658 @default.
• W2023396018 hasConcept C2778163477 @default.
• W2023396018 hasConcept C2778913445 @default.
• W2023396018 hasConcept C2779279991 @default.
• W2023396018 hasConcept C2779952775 @default.
• W2023396018 hasConcept C2780072125 @default.
• W2023396018 hasConcept C2780159708 @default.
• W2023396018 hasConcept C2984496839 @default.
• W2023396018 hasConcept C4733338 @default.
• W2023396018 hasConcept C71315377 @default.
• W2023396018 hasConcept C71924100 @default.
• W2023396018 hasConceptScore W2023396018C120863210 @default.
• W2023396018 hasConceptScore W2023396018C126322002 @default.
• W2023396018 hasConceptScore W2023396018C134018914 @default.
• W2023396018 hasConceptScore W2023396018C142724271 @default.
• W2023396018 hasConceptScore W2023396018C147583825 @default.
• W2023396018 hasConceptScore W2023396018C204787440 @default.
• W2023396018 hasConceptScore W2023396018C27081682 @default.
• W2023396018 hasConceptScore W2023396018C2776919658 @default.
• W2023396018 hasConceptScore W2023396018C2778163477 @default.
• W2023396018 hasConceptScore W2023396018C2778913445 @default.
• W2023396018 hasConceptScore W2023396018C2779279991 @default.
• W2023396018 hasConceptScore W2023396018C2779952775 @default.
• W2023396018 hasConceptScore W2023396018C2780072125 @default.
• W2023396018 hasConceptScore W2023396018C2780159708 @default.
• W2023396018 hasConceptScore W2023396018C2984496839 @default.
• W2023396018 hasConceptScore W2023396018C4733338 @default.
• W2023396018 hasConceptScore W2023396018C71315377 @default.
• W2023396018 hasConceptScore W2023396018C71924100 @default.
• W2023396018 hasIssue "6" @default.
• W2023396018 hasLocation W20233960181 @default.
• W2023396018 hasLocation W20233960182 @default.
• W2023396018 hasOpenAccess W2023396018 @default.
• W2023396018 hasPrimaryLocation W20233960181 @default.
• W2023396018 hasRelatedWork W2010098160 @default.
• W2023396018 hasRelatedWork W2023396018 @default.
• W2023396018 hasRelatedWork W2025975399 @default.
• W2023396018 hasRelatedWork W2055648105 @default.
• W2023396018 hasRelatedWork W2069123253 @default.
• W2023396018 hasRelatedWork W2117517864 @default.
• W2023396018 hasRelatedWork W2129790693 @default.
• W2023396018 hasRelatedWork W2153191047 @default.
• W2023396018 hasRelatedWork W2162168230 @default.
• W2023396018 hasRelatedWork W2202798660 @default.
• W2023396018 hasVolume "18" @default.
• W2023396018 isParatext "false" @default.
• W2023396018 isRetracted "false" @default.
• W2023396018 magId "2023396018" @default.
• W2023396018 workType "article" @default.